Objective: To investigate the expression of factor that binds to inducer of short transcripts-1 of HIV (FBI-1)in breast cancer pre- and pro-neoadjuvant chemotherapy and explore the relationship between FBI-1 expression and treatment efficacy. Methods: We collected 50 patients with breast cancer who received neoadjuvant chemotherapy before operation in the Affiliated Tumor Hospital of Guangxi Medical University from January, 2010 to December, 2014. The expression of FBI-1 in breast cancer tissues pre- and pro-neoadjuvant chemotherapy was detected by immunohistochemical staining. We compared the level of FBI-1 expression pre- and pro-neoadjuvant chemotherapy, and tried to explore its relationship with patient and tumor characteristics and treatment efficacy. Results: (1) The rate of upregulated expression of FBI-1 in breast cancer tissues was 70% (35/50). The upregulated expression of FBI-1 was related to the higher clinical stage and trend of lymph node metastasis (P<0.05), whereas not related to the age and expression of ER, PR, Ki-67, and Her-2(P>0.05); (2) the setting of FBI-1 lower expression pre-neoadjuvant chemotherapy had superior treatment outcome than the high expression setting based on either clinical assessment (86.7% vs 51.4%, P=0.027) or pathological assessment(80.0% vs 28.6%, P=0.001); (3) the rate of upregulated FBI-1 expression was significantly decreased post-neoadjuvant chemotherapy(70.0% vs 38.0%, P=0.004), with FBI-1 expression of 22 patients downregulated (62.9%); (4) the expression of FBI-1 in responded setting was significantly decreased than that in the non-responded setting based on either clinical (77.4% vs 26.3%, P=0.001) or pathological (72.7% vs 39.3%, P=0.024) assessment. The downregulation of FBI-1 was correlated to either clinical efficacy (r=0.440, P<0.01) or pathological efficacy (r=0.491, P<0.05) of neoadjuvant chemotherapy. Conclusion: In breast cancer patients receiving neoadjuvant chemotherapy, the upregulated expression of FBI-1 in breast cancer lesion is associated with clinical stage and lymph node metastasis. The neoadjuvant chemotherapy can significantly reduce the expression of FBI-1. The upregulated expression of FBI-1 may be predictive of resistance to chemotherapeutic drugs, and has predictive value for the efficacy of neoadjuvant chemotherapy in breast cancer patients.
目的： 探讨人类免疫缺陷病毒短转录诱导物连接因子1(FBI－1)在乳腺癌患者新辅化疗前后的表达情况与疗效的关系。 方法： 收集广西医科大学附属肿瘤医院乳腺外科2010年1月—2014年12月50例行新辅助化疗后再接受手术治疗的女性乳腺癌病例(中位年龄44岁)，用免疫组织化学染色法检测新辅助治疗前后乳腺癌组织中FBI－1的表达，比较化疗前后FBI－1的表达率，并分析其与一般临床特征、病理特征及临床病理疗效的关系。 结果： (1)新辅助化疗前，乳腺癌组织中FBI－1的高表达率为70%(35/50)，FBI－1的表达与临床分期、淋巴结转移状态有关(P<0.05)，而与患者年龄、雌激素受体(ER)、孕激素受体(PR)、Ki－67、人表皮生长因子受体(Her)－2状态无关(P>0.05)；(2)无论从临床疗效评估(86.7%与51.4%，P＝0.019)或是病理疗效评估(80.0%与28.6%，P＝0.001)，新辅助化疗前FBI－1低表达组化疗疗效均显著优于高表达组；(3)新辅助化疗显著降低FBI－1的高表达率(70.0%与38.0%, P＝0.004)，22例患者(62.9%)FBI－1由高表达转为低表达；(4)临床疗效显著组FBI－1表达下降较临床疗效非显著组明显(77.4%与26.3%，P＝0.001)，病理缓解显著组FBI－1表达下降较病理缓解非显著组明显(72.7%与39.3%，P＝0.024)，FBI－1表达是否下降与新辅助化疗的临床疗效(r＝0.440，P<0.01)、病理疗效(r＝0.491，P<0.05)有相关性。 结论： 接受新辅助化疗的乳腺癌患者中，FBI－1高表达与临床分期、淋巴结转移具有相关性；新辅助化疗能够显著降低乳腺癌组织中FBI－1的表达水平；FBI－1的高表达可能预示对化疗药物的耐药性，并对乳腺癌患者新辅助化疗的疗效具有预测价值。.
Keywords: Breast cancer; FBI-1; Neoadjuvant chemotherapy.